Clinical Trial Update: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of luspatercept in lower-risk myelodysplastic syndromes patients who have failed or are ineligible for ery…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: MDS, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: RECRUITING